Gold prices bounce off 3-week lows; demand likely longer term
DAIX - French biopharmaceutical company Inventiva SA, currently valued at $434 million, has outlined the objectives and conditions of its share repurchase program following the approval at the Ordinary General Meeting held on May 22, 2025. The program, which is set to last for 18 months, allows Inventiva to acquire up to 10% of its issued share capital, with a maximum number of 13,869,673 treasury shares available for purchase, considering the 45,454 shares currently held in treasury. According to InvestingPro data, the company’s stock has shown strong momentum this year with a 45% YTD return, despite challenging market conditions.
The company has set a maximum purchase price of 40 euros per share. The repurchase program’s primary aim is to facilitate liquidity and market-making under a liquidity agreement already in place since the company’s listing on Euronext. Additionally, the shares may be used for employee stock option programs or other share allocations to employees and corporate officers, as well as to potentially reduce the company’s capital by canceling acquired shares. InvestingPro analysis reveals the company maintains impressive gross profit margins of 90%, though it’s currently experiencing rapid cash burn.
Inventiva, which specializes in developing oral small molecule therapies, is currently conducting a pivotal Phase 3 clinical trial for lanifibranor, a treatment for NASH, a progressive chronic liver disease. The company is listed on compartment B of the regulated market of Euronext Paris (Euronext: IVA) and on the Nasdaq Global Market in the United States (NASDAQ:IVA), where it trades at $3.11 per share. Recent financial data shows a significant revenue decline of 38% in the last twelve months, reflecting the company’s development stage status.
The company’s future plans, as stated in the press release, include purchasing or selling shares under the liquidity agreement, fulfilling obligations related to stock option programs, delivering shares upon the exercise of rights attached to securities, and potentially reducing capital through share cancellation. Inventiva also reserves the right to undertake any transactions permitted by law or market practices, with a commitment to inform shareholders through press releases should such transactions occur.
This announcement is based on a press release statement from Inventiva and provides investors with the latest details on the company’s share repurchase program and its ongoing clinical trial endeavors.
In other recent news, Inventiva SA has successfully completed patient enrollment for its NATiV3 Phase 3 clinical trial, surpassing initial targets. The trial enrolled 1,009 patients in the main cohort and 410 in an exploratory cohort, marking a significant milestone for the company’s lead drug candidate, lanifibranor. Topline results from this trial are anticipated in the second half of 2026. This development has also allowed Inventiva to access a second tranche of approximately €116 million in structured financing, crucial for extending its cash runway to the third quarter of 2026. Analysts from Guggenheim have adjusted their price target for Inventiva to $9.00, maintaining a Buy rating, while Stifel analysts reiterated a Buy rating with a $17.00 price target. Both firms express optimism about lanifibranor’s potential, citing positive safety reviews and promising interim data. The NATiV3 trial’s design has been praised for its low dropout rates and comprehensive scope, which will provide a robust clinical profile for lanifibranor. The completion of enrollment and favorable analyst ratings reflect confidence in Inventiva’s prospects and the potential of its treatment for MASH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.